Monday 21 September 2015, Amsterdam
The report, now available on ASDReports, recognizes the following companies as the key players in the Global Insomnia Market: Eisai, Merck, Pfizer, Sanofi and Takeda
Other Prominent Vendors in the market are: Astellas, Biocodex, ECR Pharmaceuticals, Dainippon Sumitomo, Fidia Farmaceutici, Flynn Pharma, Johnson & Johnson, Juste, Meda, Medice Arzneimittel Putter, Minerva Neurosciences, Neurim, Pernix Therapeutics, Purdue Pharma, SkyePharma, Somnus Therapeutics, Paratek Pharmaceuticals, and Vanda Pharmaceuticals.
Commenting on the report, an analyst said: “Vendors are entering into strategic alliances with other vendors and universities for the research, development, manufacture, and distribution of drugs. The trend is predicted to continue during the forecast period.”
According to the report, People’s growing awareness of the importance of sleep will motivate individuals with insomnia to seek treatment. The low diagnosis rate for insomnia is due to the lack of awareness and identification of symptoms. Therefore, awareness campaigns and initiatives by hospitals and healthcare centers will help people understand the consequences of sleep disturbances and motivate them to seek treatment, thus driving the global insomnia drugs market.
Further, the report states that the branded drugs indicated for insomnia are expected to lose their patents during the forecast period. Patent expiry is poised to impact the market significantly by slowing down the market’s growth rate.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
ASDReports.com Media contact: S. Koopman -
Marketing and Communications
ASDReports.com / ASDMedia BV - Veemkade 356 - 1019HD Amsterdam - The Netherlands
P : +31(0)20 486 1286 - F : +31(0)20 486 0216 - E : firstname.lastname@example.org
back to News